JP2013508411A - 癌治療の効果を高め、その副作用を軽減する方法および栄養製剤 - Google Patents

癌治療の効果を高め、その副作用を軽減する方法および栄養製剤 Download PDF

Info

Publication number
JP2013508411A
JP2013508411A JP2012535426A JP2012535426A JP2013508411A JP 2013508411 A JP2013508411 A JP 2013508411A JP 2012535426 A JP2012535426 A JP 2012535426A JP 2012535426 A JP2012535426 A JP 2012535426A JP 2013508411 A JP2013508411 A JP 2013508411A
Authority
JP
Japan
Prior art keywords
patient
meal
cancer
chemotherapy
predetermined period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508411A5 (enExample
Inventor
ディー． ロンゴ，ヴァルトル
リー，チャンハン
Original Assignee
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ サザン カリフォルニア filed Critical ユニバーシティ オブ サザン カリフォルニア
Publication of JP2013508411A publication Critical patent/JP2013508411A/ja
Publication of JP2013508411A5 publication Critical patent/JP2013508411A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012535426A 2009-10-22 2010-10-22 癌治療の効果を高め、その副作用を軽減する方法および栄養製剤 Pending JP2013508411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US61/254,154 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (2)

Publication Number Publication Date
JP2013508411A true JP2013508411A (ja) 2013-03-07
JP2013508411A5 JP2013508411A5 (enExample) 2013-11-21

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535426A Pending JP2013508411A (ja) 2009-10-22 2010-10-22 癌治療の効果を高め、その副作用を軽減する方法および栄養製剤

Country Status (13)

Country Link
US (2) US20110118528A1 (enExample)
EP (1) EP2490684B1 (enExample)
JP (1) JP2013508411A (enExample)
CN (1) CN102753162A (enExample)
AU (2) AU2010310515B2 (enExample)
BR (1) BR112012009423A2 (enExample)
CA (1) CA2779282C (enExample)
DK (1) DK2490684T3 (enExample)
ES (1) ES2659353T3 (enExample)
PL (1) PL2490684T3 (enExample)
PT (1) PT2490684T (enExample)
RU (1) RU2549954C2 (enExample)
WO (1) WO2011050302A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509671A (ja) * 2014-03-28 2017-04-06 ウニベルシタ デリィ ストゥディ ディ ジェノバ カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
JP2017513460A (ja) * 2014-03-06 2017-06-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP2019504073A (ja) * 2016-01-12 2019-02-14 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
JP2023516236A (ja) * 2019-12-13 2023-04-19 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
NZ715431A (en) 2013-07-01 2022-02-25 Univ Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
MX2016012896A (es) * 2014-04-02 2017-05-12 Univ Southern California Autoinmunidad y tratamiento de la esclerosis multiple.
CA3108664A1 (en) * 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
CA2984891A1 (en) 2015-05-06 2016-11-10 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
AU2016328683A1 (en) * 2015-09-21 2018-05-10 Ifom Fondazione Istituto Firc Di Oncologia Molecolare New therapeutic strategies against blood cancer
AU2017219732B2 (en) 2016-02-15 2022-01-20 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
KR20200125966A (ko) 2018-03-15 2020-11-05 유니버시티 오브 써던 캘리포니아 염증 및 ibd 병리의 역전을 촉진하는, 물만 섭취하는 금식이 아닌 금식 모방 식이요법 (fmd)
DE212018000421U1 (de) * 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
AU2019376681B2 (en) 2018-11-09 2025-07-24 L-Nutra Inc. Nutrition bar for intermittent fasting-mimicking
US12185747B2 (en) 2019-04-30 2025-01-07 University Of Southern California Fasting-mimicking diet (FMD) as an intervention for Alzheimer's disease (AD)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
KR20220098682A (ko) * 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
CN116133653A (zh) 2020-06-04 2023-05-16 菲思治疗公司 治疗癌症的个体化方法
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
US20240000125A1 (en) * 2020-12-17 2024-01-04 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515510A (ja) * 1997-03-17 2001-09-18 ビーティージー・インターナショナル・リミテッド 治療用組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
AU5319499A (en) * 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
ES2891733T3 (es) * 2007-03-28 2022-01-31 Univ Southern California Inducción de la resistencia diferencial al estrés y usos de la misma
MX2010005768A (es) * 2007-11-26 2010-06-11 Nestec Sa Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515510A (ja) * 1997-03-17 2001-09-18 ビーティージー・インターナショナル・リミテッド 治療用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERVING VEGETARIANS A GUIDE FOR THE CATERING INDUSTRY,2006,, JPN6014039547, 2006, pages 1 - 16, ISSN: 0002901105 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513460A (ja) * 2014-03-06 2017-06-01 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP2021020926A (ja) * 2014-03-06 2021-02-18 ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP7038432B2 (ja) 2014-03-06 2022-03-18 ユニヴァーシティ オブ サザン カリフォルニア 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP2017509671A (ja) * 2014-03-28 2017-04-06 ウニベルシタ デリィ ストゥディ ディ ジェノバ カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
JP2020147598A (ja) * 2014-03-28 2020-09-17 ウニベルシタ デリィ ストゥディ ディ ジェノバ カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
JP2019504073A (ja) * 2016-01-12 2019-02-14 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
JP2021183622A (ja) * 2016-01-12 2021-12-02 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
JP2023516236A (ja) * 2019-12-13 2023-04-19 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物
JP7376718B2 (ja) 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物

Also Published As

Publication number Publication date
US20110118528A1 (en) 2011-05-19
CN102753162A (zh) 2012-10-24
PL2490684T3 (pl) 2018-07-31
EP2490684A2 (en) 2012-08-29
RU2549954C2 (ru) 2015-05-10
AU2016201607B2 (en) 2017-11-30
PT2490684T (pt) 2018-04-02
WO2011050302A2 (en) 2011-04-28
EP2490684B1 (en) 2018-01-03
BR112012009423A2 (pt) 2017-06-13
US20210209516A1 (en) 2021-07-08
CA2779282C (en) 2017-12-05
RU2012118588A (ru) 2013-11-27
AU2010310515A1 (en) 2012-05-17
AU2010310515B2 (en) 2016-01-07
ES2659353T3 (es) 2018-03-14
CA2779282A1 (en) 2011-04-28
AU2016201607A1 (en) 2016-03-31
DK2490684T3 (en) 2018-04-09
EP2490684A4 (en) 2016-05-04
WO2011050302A3 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
JP2013508411A (ja) 癌治療の効果を高め、その副作用を軽減する方法および栄養製剤
JP7038432B2 (ja) 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
JP7168943B2 (ja) 癌における食事療法の開発
ES2822178T3 (es) Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
Brandhorst Fasting and fasting-mimicking diets for chemotherapy augmentation
US10172839B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP2021008491A (ja) 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食（ｆｍｄ）およびグルコース低下薬
Evangeliou et al. Restricted ketogenic diet therapy for primary lung cancer with metastasis to the brain: a case report
JP2019504073A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
Cipolla et al. Treating metastatic castration-resistant prostate cancer with novel polyamine-free oral nutritional supplementation: Phase I study
Kiryttopoulos et al. Successful application of dietary
Van der Meij et al. The effects of supplementation of n-3 polyunsaturated fatty acids on clinical outcome parameters in patients with cancer: a systematic review
HK1233488B (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
Healthcare et al. Dietary Supplements
JP2020059699A (ja) 難治性癌の食事療法およびそれに適した治療食
Wright Evidence-Based Treatment of Digestive Symptoms in Pancreatic Cancer Patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630